Oprah Winfrey is leaving WeightWatchers board and giving away all her stock at critical weight loss moment
Join us at the first-ever CNBC Changemakers event on April 18th in NYC.
For all of the promise associated with new weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound in treating obesity, there's a very big risk printed right on the label at the requirement of the FDA: patients should be prescribed these so-called GLP-1 drugs only in combination with, not as a replacement for, diet and exercise programs.
The boom in these drugs — with more poised to enter the pharmacy market and the employer-based insurers still in the early days of adding coverage for workers — is just getting started. Does that make it the greatest opportunity a diminished WeightWatchers has seen in a long time to reinvigorate its business model, or an existential threat unlike any it has faced in its history as obesity is treated more like a chronic disease requiring medicine?
When WW CEO Sima Sistani — who was named to the inaugural CNBC Changemakers list on Wednesday — made the acquisition of Sequence, now WeightWatchers Clinic, last March to get the company into the clinicals business, she made a move that the company needed.
The 2024 CNBC Changemakers: See the full list of 50 women transforming business
Fortune 500 CEOs, Naomi Osaka and Alex Cooper share a success secret
How we chose the Changemakers
Even Wall Street analysts skeptical of WW's stock chart and a market cap that is currently dwarfed by outstanding debt roughly five times its valuation — though not coming due for several years yet — agree that Sistani pulled the trigger at the right time on the right kind of business. Having a link to the weight-loss drug prescription market is a must. But will Americans trust the most iconic brand in the legacy weight-loss